AB INBEV - BUY TOP PICKS | EUR65 Q1 revenue growth of 11.1% - full year outlook confirmed
AB INBEV - BUY TOP PICKS | EUR65Q1 revenue growth of 11.1% - full year outlook confirmed
Q1 revenue growth of 11.1% and EBITDA growth of 7.4%
Brazil revenues grew strongly but there was expected weakness in both the US and China
Outlook confirmed – revenue growth ahead of EBITDA growth of between 4 and 8%
AB Effectenbeteiligungen AG is an Austria-based company that invests in European companies. The Company is engaged in the investment in undervalued small-cap and micro-cap companies, in medium-sized companies with a growth potential, as well as in pre-initial public offering (IPO) companies. In the fiscal year ended on December 31, 2009, AB Effectenbeteiligungen AG's portfolio included Rhoen Kliniken AG, a Germany-based hospital operator, Realtime Technology AG, a Germany-based provider of visualization technologies and services for industrial applications in the automobile, aviation and consumer goods sectors and RIB Software AG, a Germany-based specialist in building construction, plant engineering and infrastructure management software.
Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.